Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Evident names 5th Annual Image of the Year Award winners
View the six winning entries in Evident's 5th Annual Image of the Year Award — a...
Fellowships and scholarships support women in science
The L'Oréal-UNESCO For Women in Science initiative has honoured five trailblazing...
2024 GSK Award recognises neurodegeneration researcher
Professor Matthew Kiernan won the 2024 GSK Award for Research Excellence for his work in...
